Bio-distribution of pharmacologically administered recombinant factor VIIa (rFVIIa).

ABSTRACT:

Background

Recent clinical studies suggest that the prophylactic use of recombinant factor VIIa (rFVIIa) markedly reduces the number of bleeding episodes in hemophilic patients with inhibitors. Given the short biological half-life of rFVIIa, it is unclear how rFVIIa could be effective in prophylactic treatment.

Objectives

To examine the extravascular distribution of pharmacologically administered rFVIIa to obtain clues on how rFVIIa could work in prophylaxis.

Methods

Recombinant mouse FVIIa tagged with AF488 fluorophore (AF488-FVIIa) was administered into mice via the tail vein. At different time intervals following the administration, mice were exsanguinated and various tissues were collected. The tissue sections were processed for immunohistochemistry to evaluate di

SUBMITTER: Gopalakrishnan R 

PROVIDER: S-EPMC2849270 | biostudies-literature | 2010 Feb

REPOSITORIES: biostudies-literature